These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35235820)

  • 21. Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.
    Dhruva SS; Darrow JJ; Kesselheim AS; Redberg RF
    J Gen Intern Med; 2022 Dec; 37(16):4176-4182. PubMed ID: 35138547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
    Kandemir EA
    J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2020: A Record Year for Drug Approvals.
    Losben NL
    Sr Care Pharm; 2021 Apr; 36(4):174-175. PubMed ID: 33766189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
    Nierengarten MB
    Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1619-1632. PubMed ID: 36951997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study.
    Lexchin J
    Health Policy; 2022 Oct; 126(10):1018-1022. PubMed ID: 35970691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2023 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.
    Bharate SS
    Drug Discov Today; 2021 Feb; 26(2):384-398. PubMed ID: 33221522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
    Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
    Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.
    Bharate SS
    Pharm Res; 2021 Aug; 38(8):1307-1326. PubMed ID: 34302256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and clinical application of new drugs approved by FDA in 2023.
    Wang YT; Yang PC; Zhang YF; Sun JF
    Eur J Med Chem; 2024 Feb; 265():116124. PubMed ID: 38183778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the FDA 2018 New Drug Approvals.
    Bedair A; Mansour FR
    Curr Drug Discov Technol; 2021; 18(2):293-306. PubMed ID: 31793428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
    Benjamin DJ; Xu A; Lythgoe MP; Prasad V
    JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review.
    Brown BL; Mitra-Majumdar M; Joyce K; Ross M; Pham C; Darrow JJ; Avorn J; Kesselheim AS
    J Health Polit Policy Law; 2022 Dec; 47(6):649-672. PubMed ID: 35867548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.